The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.
Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.
Clinical researchers at Scottsdale Healthcare and TGen have announced the results of two clinical trials that show promise for patients battling cancer.
As many as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, according to current multi-center outcomes data.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
One of the early, successful uses of nanoparticles has been to develop delivery vehicles capable of ferrying large amounts of water-insoluble drugs to tumors.
Albumin nanoparticles have recently proven their mettle as anticancer agents with the 2005 approval of Abraxane to treat metastatic breast cancer.
Brain cancer is one of the most difficult malignancies to detect and treat, in large part because of the difficulty in getting imaging and therapeutic agents past the so-called blood-brain barrier and into the brain.
According to a new report by NanoMarkets, an industry consultancy based here, nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009 and grow to $2.5 billion in 2012.
American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.
Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.
American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.
Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).
American Pharmaceutical Partners, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cladribine Injection.